Phase II trial of carboplatin, everolimus, and prednisone in metastatic castration-resistant prostate cancer pretreated with docetaxel chemotherapy: a prostate cancer …

U Vaishampayan, D Shevrin, M Stein, L Heilbrun… - Urology, 2015 - Elsevier
Objective To conduct a phase II trial of the combination of carboplatin, prednisone, and
everolimus in metastatic castrate–resistant prostate cancer (mCRPC) as mTOR inhibition …
被引用次数：38 相关文章

Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate …

U Vaishampayan, D Shevrin, M Stein, L Heilbrun… - Urology, 2015 - goldjournal.net
Objective To conduct a phase II trial of the combination of carboplatin, prednisone, and
everolimus in metastatic castrate–resistant prostate cancer (mCRPC) as mTOR inhibition …

Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate …

U Vaishampayan, D Shevrin, M Stein, L Heilbrun… - Urology, 2015 - infona.pl
To conduct a phase II trial of the combination of carboplatin, prednisone, and everolimus in
metastatic castrate–resistant prostate cancer (mCRPC) as mTOR inhibition can overcome …

Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate …

U Vaishampayan, D Shevrin, M Stein, L Heilbrun… - Urology, 2015 - hero.epa.gov
OBJECTIVE: To conduct a phase II trial of the combination of carboplatin, prednisone, and
everolimus in metastatic castrate-resistant prostate cancer (mCRPC) as mTOR inhibition can …

Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate …

U Vaishampayan, D Shevrin, M Stein, L Heilbrun… - Urology, 2015 - europepmc.org
Objective To conduct a phase II trial of the combination of carboplatin, prednisone, and
everolimus in metastatic castrate-resistant prostate cancer (mCRPC) as mTOR inhibition can …
[PDF] researchgate.net

[PDF][PDF] Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A …

U Vaishampayan, D Shevrin, M Stein, L Heilbrun… - Urology, 2015 - researchgate.net
OBJECTIVE—To conduct a phase II trial of the combination of carboplatin, prednisone, and
everolimus in metastatic castrate–resistant prostate cancer (mCRPC) as mTOR inhibition …

Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated with Docetaxel Chemotherapy: A Prostate …

U Vaishampayan, D Shevrin, M Stein, L Heilbrun… - …, 2015 - researchwithrutgers.com
Objective To conduct a phase II trial of the combination of carboplatin, prednisone, and
everolimus in metastatic castrate-resistant prostate cancer (mCRPC) as mTOR inhibition can …
[HTML] nih.gov

[HTML][HTML] Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A …

U Vaishampayan, D Shevrin, M Stein, L Heilbrun… - Urology, 2015 - ncbi.nlm.nih.gov
OBJECTIVE To conduct a phase II trial of the combination of carboplatin, prednisone, and
everolimus in metastatic castrate–resistant prostate cancer (mCRPC) as mTOR inhibition …

Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate …

U Vaishampayan, D Shevrin, M Stein, L Heilbrun… - …, 2015 - pubmed.ncbi.nlm.nih.gov
Objective To conduct a phase II trial of the combination of carboplatin, prednisone, and
everolimus in metastatic castrate-resistant prostate cancer (mCRPC) as mTOR inhibition can …

Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate …

U Vaishampayan, D Shevrin, M Stein, L Heilbrun… - Urology, 2015 - europepmc.org
Objective To conduct a phase II trial of the combination of carboplatin, prednisone, and
everolimus in metastatic castrate-resistant prostate cancer (mCRPC) as mTOR inhibition can …